cfDNA capture with msX™
PIONEERING POLYMER TECHNOLOGY FOR DIRECT CAPTURE OF NUCLEIC ACIDS
msX™ is a groundbreaking suite of polymers designed to unleash the full potential of liquid biopsy. Our patented polymers capture cfDNA directly from biological fluids without additional reagents, delivering enhanced cfDNA yields with exceptional sample stability and minimal pre-analytical processing. msX™ offers new, game-changing possibilities for non-invasive genetic testing and personalised medicine.
See more of the big picture
High quality, high yield samples collected with msX™ enable expanded testing menus, deeper sequencing, and even PCR-free workflows. msX™ selectively targets cfDNA, improving signal to noise ratios by minimising high molecular weight and cellular DNA contamination. As msX™ does not bind proteins, cells or other sample components, innovative new methods such as multi-omic assays for precious samples and in-vivo cfDNA capture become possible.
No more wasted samples
Sample volumes are unlimited with msX™ coatings as no binding reagents or pre-analytical processing are required. The entire sample can be used, even where this exceeds 1 litre. As a result, msX™ offers simpler workflows and increased yield and quality of cfDNA which reduce the chance of sample failure.
cfDNA bound by msX™ can be stored stably for up to 90 days at room temperature before being concentrated into a PCR- and NGS-compatible, lab-ready format.
A bespoke solution
msX™ coatings are adaptable to many substrate formats including solid matrices, beads, and automated solutions. Polymers can be tailored to specific applications and biological fluids, ensuring optimal yield and quality. As msX™ polymers are designed to capture only cfDNA and resist biofouling, they are especially suitable for large volume flow-through solutions. Our polymers are produced to high standards under an ISO 13485 compliant quality management system.
Making a difference to cancer patients
Minimally invasive liquid biopsy can relieve significant financial and operational burdens on healthcare providers and improve patient compliance and wellbeing. However, current techniques limit its use as they suffer from restricted sample volumes, poor quality samples and a lack of sample diversity. msX™ helps to overcome these limitations and break the boundaries of liquid biopsy, enhancing its use for diagnosis and monitoring of disease states, and the development of personalised treatment plans.